Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, and SHINE entered into a strategic agreement for the future supply of molybdenum-99 (Mo-99). The supply agreement marked Lantheus’ first with a prospective U.S. supplier of Mo-99.
Under the terms of the supply agreement, SHINE will provide Mo-99 produced using its proprietary low enriched uranium (LEU)-solution technology for use in Lantheus’ TechneLite® generators once SHINE’s facility becomes operational.
This definitive agreement with Lantheus signals the beginning of a new era for the production of radioisotopes in North America, in which a private producer can thrive. This agreement, along with another agreement earlier this year, show that SHINE is important to the future of medical isotope generation,” said Greg Piefer, founder and Chief Executive Officer of SHINE.